Ambu

Ambu A-S will release its quarterly results on 5 November 2026. Two analysts on average expect earnings per share of 0.862 DKK, up from 0.430 DKK in the year-ago quarter. Six analysts forecast revenue to rise 13.54 percent to around 1.66 billion DKK. For the past fiscal year, the analyst consensus is 2.40 DKK earnings per share and revenue of 6.44 billion DKK. » Mere på finanzen.net

Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » Mere på de.investing.com

Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » Mere på finanzen.net

Ambu reported organic revenue growth of 8.6% in Q1 2025/26 (reported 3.2% after currency impact) and total revenue of DKK 1,558m. The driver was the Endoscopy Solutions segment with 14.4% organic growth; Anesthesia & Patient Monitoring was flat. EBIT margin before special items fell to 10.5%; adjusted for tariffs and currency effects it would be 15.2%. Free cash flow was DKK 13m. Ambu confirmed its full-year outlook of 10–13% organic revenue growth and a target EBIT margin of 12–14%, but continued to see currency and tariff risks. » Mere på de.investing.com

Ambu reports organic revenue growth of 8.0% year-to-date and 7.3% in the second quarter, with the endoscopy solutions segment accounting for 63% of revenue. Reported growth in Q2 was dampened to 1.2% by adverse exchange rates. Reported EBIT margin was 11.0%, adjusted to 14.5%, and free cash flow amounted to DKK 104 million. The company maintains its guidance, sees opportunities in the shift to single-use endoscopes, and cites exchange rates, tariffs and supply-chain inflation as key risks. » Mere på de.investing.com